IFACT: Incidental Findings in Advanced Cancer Therapy
The proposed study, IFACT - Incidental Findings in Advanced Cancer Therapy, will address this research gap by examining MSK patients' attitudes, preferences, and information needs regarding incidental findings arising from tumor genomic profiling.
Checked against the public recordLast updated Feb 13, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Interventions being studied
- Behavioral: Semi-structured interview
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: Part 1: * Patient enrolled on MSK protocol #12-245 * Living patient age 18 or older * Patient diagnosed with breast cancer, colorectal cancer, bladder cancer, or lung cancer * Patient residing in New York metro-area Part 2: * Living patient age 18 or older * Consented to Part C of IRB#12-245 and has received results regardless if thereir was a pathogenic variant * Patient diagnosed with cancer type approved for IRB#12-245 Part C (which are currently breast cancer, gynecological cancer, prostate cancer, and GU non-prostate cancer)breast cancer, colorectal cancer, bladder cancer, or lung cancer * Patient residing in New York metro-area Exclusion Criteria for Part 1 and 2: * Non-English speakers because we do not have the resources to conduct and translate the interviews into other languages. * Patient unwilling or unable to provide informed consent.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Memorial Sloan Kettering Cancer CenterNew York, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 13, 2023. Always confirm current availability with the study team.